We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Santhera Presents New Data on MC-4R Antagonist Program for Treatment of Cancer Cachexia

News   Dec 08, 2009

 
Santhera Presents New Data on MC-4R Antagonist Program for Treatment of Cancer Cachexia
 
 
Advertisement
 

RELATED ARTICLES

Phase 3 Clinical Trial of Belimumab for Lupus Nephritis Reports Positive Results

News

Results from the largest Phase 3 lupus nephritis clinical trial ever conducted were announced, September 16. The study, found positive results of the efficacy and safety of the drug belimumab in patients with active lupus nephritis, a condition that causes inflammation in the kidneys of patients with systemic lupus erythematosus.

READ MORE

Biologic Therapy for Psoriasis May Also Have Applications in Heart Disease

News

Patients with psoriasis treated with biologic therapy, which are protein-based infusions to suppress inflammation, had a significant reduction in high-risk plaque in heart arteries, over one-year, according to new research.

READ MORE

Team Identifies Potential Pitfall in Emerging Treatment for Cancer and Inflammation

News

Whilst studying an emerging drug target in cancer and inflammation, researchers discovered the unintended activation of a protein called ERK5, this activation was due to the binding location of the inhibitors. ERK5 inhibitors that bound to the kinase domain of the protein led to the protein being shuttled to the cell nucleus and activated. Blocking ERK5 has therapeutic potential, but activating it could have undesirable consequences in terms of stimulated unwanted cell growth.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE